McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “Patent Docs: Federal Circuit construes patent litigation provisions of biosimilars law” that appears in the September 2015 online edition of DDNEWS. Last month, the Court of Appeals for the Federal Circuit (which has national jurisdiction over U.S. patent law) interpreted the provisions of the Biologics Price Control and Innovation Act (BPCIA) in the case of Amgen v. Sandoz. In doing so, the court limited the information available to biologic drugmakers regarding a competitor’s application for a biosimilar product (adopting Sandoz’s argument). On the other hand, the decision extended the statutory exclusivity period enjoyed by innovator biologic drug makers relating to when the biosimilar applicant can enter the marketplace (as Amgen argued). view the article